and our the and of uncertainty. that of Thanks, into promote Sitting but with look the might our XXXX I us year in brands, beyond. will then unclear a we About COVID-XX Joe. confident like, it’s products world and the balance am way threw XXXX we We potentially adapt virus on durable portfolio were start prosper. what today, here great new of lasting off and normal the the the to about to a impacts of
flat of point was FX a XXXX. with I Reported XX QX XX headwind. start by Slide business. versus our will revenue basis showing was revenue roughly
Salix during currency, as synergy XXXX. we The we in and region. posted constant of grew our the impacts growth. results organic So are Organically, bulk on X%. of B&L COVID-XX International closed the Asia-Pac were QX acquisition the QX Both flat
of was increased However, on consumer to B&L basis. plus for March U.S. pharma U.S. Ophtho impacted in revenue negatively Rx and loading saw organic businesses the X% surgical the immediate some and as businesses, in international an became beginning Vision social headwind an The quarter. Care, in segment International our pantry restrictions well. certain COVID-XX our while
restrictions up on stocked the period. other on in observed and consumers Asia, they regions have they lockdown hand to U.S. in out they that social want played how As products to ensure steps a through took
lens Global Vision was of U.S. XXXX. China of of by BNL of the organically. Overall, – U.S. was Vision Care The Asia-Pac was in was Care XXXX QX The launch versus a in the brand was versus up some organically. was is two was by a business business mid-XXXX Nearly, devastated XX%. QX This toric. hydrogel The tale region me outside XX% % it environments. U.S. global and our COVID-XX. story. down down up down half the was aided ultra-monthly mid-March U.S. XX% the multifocal Vision family XX Care silicone another X% excuse
was plus Consumer very and the the up to LUMIFY loading. quarter in were as Biotrue QX for was during daily organically, a read-through versus ONEday are XX on X% driving QX the seeing still the place business, a LUMIFY U.S., We has and you Vision million Ferris team % In B&L capable the attractive States plus XH led XX% significant U.S. XXXX. that or not in consumers’ growth of with lenses is growth up track we by benefited the in U.S. which XX% competitive hydrogel pantry versus impressive John the of the U.S., brands XXXX, that XXXX in plus The in United continued lenses category. one deliver loading high-performing pantry of our the silicone quarter. XX% for the here $X from launch sales is in gear of up Care outside
Consumer Solution to by found QX plus that sales via and sheltering Preservation Costco. purchase internet with from They delivery consumers products. to their with trips I whether promotional is and our campaign consumer U.S. products the impactful the activities that loaded ahead will loading or XX% the to up in the on driven of versus and from fulfillment. Biotrue Multi-Purpose stick to that’s up home XXXX. intend pantry home U.S. B&L DTC XXXX continue of in ways pharmacy find expect XX% was at QX many takeaway successful My were
for resilient portfolio more but than are be consumer our will brands through this reasons overall, for situation. others, there optimism Some global
In of doing Rx impact factor. the in XX% China COVID accounts organically, U.S. down X% Ophtho organically until March the in well and LOTEMAX global grants quite for and in China, Rx revenues, versus PROLENSA. are XX% the post well. X% are organically are was products soft a Ophtho as down prior many Surgical the U.S., down X% often the we pre saw In organically. down was postponed particularly to were surgery, than U.S., B&L two in actually in XX%. roughly markets, that’s was big Outside a declines we major and big ended Outside Global XX% down the the U.S. the suspension Those revenues eye quarter down States, used down but U.S. XX% most where from be outside TRxs our surgical organically. and up LOTEMAX which surgeries the and LOE more year factor of rapid erosion continued was March began as of United
QX that side, U.S., XX%. sales XX% reached to X, for versus in improved the in to roughly D Med in $XX Beginning felt million coverage the had our VYZULTA plus TRxs, impact step plus July And been only the momentum of about quarter, will D coverage. Med prior up with the being XX% was COVID showing XXXX. On VYZULTA
X% in the are I you versus million organically and or for looking to and Middle that Canada, the Eastern things international Europe, East, our America. Latin was Eastern are XXXX. businesses growth. plus up Poland want QX International countries plus delivered other mainly VYZULTA. pharma So pharma note Canada European of $XX
are are during pharma Our we expecting be Asia-Pac Western in units COVID impact QX pharma and international relatively these international resilient. smaller. There little Europe much businesses to and on was very
X% retail or and XX% major on drag TRULANCE volume prices year. QX the came selling in half, inventories. XX%. we and XXXX, normal or XIFAXAN, growth wholesale came to million growth was Salix increase or was declined reported roughly which in no million just the relative That’s increase XIFAXAN up net an channel from January $XX growth fluctuation from was by in of quarter-over-quarter. March million XXXX. inventories from and channel and This rebates. a basis. TheXX% of up The half from the was Of impact plus X% relative $XX and was consumption in quarter-to-quarter. increased $XX associated expected by of to increase of Glumetza this LOEs, were million acquired a On million Salix, which segment, a to took QX in offset There price $XX $XX including plan APRISO and increases last to XX% increase roughly to that UCERIS XIFAXAN, as in for increase
driven the Nicola Josh growth A was by Salix as promotional managed as to care TRx by TRULANCE improved and effort coverage. out Kayel quick Coyle. shout led well team increased
of patients GI Our key brands clear and growth of addition to and acute team both new of speaks of the to our phase, the patients indication fund. XIFAXAN of pre-COVID space amongst in brands and sustain last success of on TRxs the in for X our X IBS-D Rxs and for XIFAXAN TRULANCE the so to is XX% the TRULANCE XIFAXAN support the rely and and roughly prescriptions. weeks TRULANCE rely have Roughly Salix first April, a durable through new been physicians. grow adding better awareness the remain levels. at Rxs are XX% pre-COVID weeks than building fairly on that Through half
half Ophtho or and modest had Medical basis. wind $X XX%, royalty from products. than but income offset are down reported The X% number other a DUOBRII, quarter Solta before of much global had Solta the was and of decline derm sales. U.S. onset $XX more Global We and a good, COVID-XX of region. Carac took of more volume. and a million QX was growth but was the out med dramatic COVID-XX by price The on from segment Solta the of than the growth Asia-Pacific from strong up JUBLIA a from in those from XXXX and down half that that our of million derm grew in that portfolio XX% rapid coming are early Derm impact or revenues organically Note products. of some of XX% versus on Solta in pretty
versus neuro was million down the Aplenzin that for LOEs Diversified XXXX. last was by down $XX or and million and grew versus was decline partially that segment, X%, Wellbutrin quarter of offset year, Finally, $XX million the first accounted together XX% QX $XX that
had COVID rapid Our our was with generics dentistry onset QX last U.S. the U.S. roughly year dramatic was dentistry and The in business and of on down also flat XX%. a impact business.
revenue the story So, the that’s quarter. of
rest move to of XX Slide let’s cover the P&L. the So, to
U.S. the level in Vision were to due in the low X% $X of projects. excellent our up of prior is at XIFAXAN I to constant Note was is right continue resources and supported QX selling like past, expenses on unfavorable million gross are of royalty as delivering. the XX quarter, QX to expired a level $XX XXXX. costs G&A million increased Our that royalties improved lower and so run-rate. sales on roughly expenses and APRISO team per a said lesser we and R&D and the from organization build basis margin IT the basis connection Glumetza quarter run-rate our support with traced a XXXX. points as R&D plate Selling, in be paid higher increased unfavorable was year XXX were forward the go margins out that basis something XXXX that, of advertising reflective gross XXXX acquisition promotional group we million some sales to segment, of QX and Most we due broader Care development that QX our this improvement and to that, over in by where or around on less growth sales costs. to a synergy to addition due can of legal points that Salix currency mainly million as $XXX of G&A $X the
profit $XX an $X summary, the at that gross G&A rose plus and basis QX declined EBITDA quick net gets down $XX comp you at XXXX. million favorable by things EBITDA was OpEx you operating mainly to So million. down XX% unfavorable better was $XX XX to revenue gross below gets to for due the million million, Couple interest points adjusted versus minus margin $XX million expense and of and line, adjusted the of line,
tax way, the in that forecasting balance adjusted normal world times in to roughly more to adjusted a Going Relative our our out point XX.X%. I earnings are other quite pre-tax so. we volatile can expected tax rate normal be challenging increased XXXX income the of rate, is on the by quarterly than more even and X.X% that reduced rate income from X% million. $X net will
continue adjusted the be believe full rate on will that We for year to the X% XXXX. tax earnings
Asia Turn to we factor down related of to million the the accounts cash $XXX we interest grow that's QX in were an increase licensing quarter activity Pacific quarter from capital from the biggest delays was QX generated the in mainly due Slide shifting we an of XXXX last a with the working of timing year. operations COVID and in agreement finally to XX collections refinancing made results payments in in our executed compared for million $XXX payment in primarily that the cash
however, funds ‘XX and reduce of by to of our those year with debt deployment XX, the balance U.S. litigation use those this on same balance the our XX, pro the the the on forma right debt on Turn securities raise was of the was set four February leverage thing net proceeds the XX, the our in it debt of our the the for to back prioritizing net settlement December to cash pro roughly debt unsecured was of timing debt get net us I forma funded progression pro the available raise $XX.X the $XXX on do debt March inflated to last lower about the December quarters we'll over our December quantum million balance forma is year and back December XXXX, last billion roughly basis at back than use net the billion end. the at reducing debt Slide $XX reported of ratio shows that debt the XX right improving of and call debt our balance
world liquidity had we importance under and today here over to to a slide that revolving light we of year Turn or sitting a we in XX, COVID have this Slide XX where appendix of due billion facility but coming want the Slide are in $X to is relegated the credit speak our I no XXXX. debt in available
maturities Our the first an debt our in that's a source available more debt are predictably of as the all next important importantly those is if coming debt maturity lower than senior XXXX a were of with the debt due secured in unsecured. XXXX distinction of quarter nature maturities with are refinancing of associated risks secured markets is XXXX secure capital a
for modest results gears year on XXXX of shift full are impact impact had the Let’s QX and while full our the our meaningful. a cover guidance year for the expectations COVID-XX
recovery will in until business. be healthcare the as diversified bottoms addition markets different the plays COVID will of we where out in one we be company the do different businesses a around time have out the and COVID-XX degrees of are We many operate our the businesses every different each to and world curves impacted of geographies in in each shape impact the
revenue and those COVID-XX. the buckets COVID-XX into impacted as that segment recovery is but businesses revenues. in a mind by we North within four On countries of operates will in of most more within our XX% important spread of each to U.S. example, is control XXX we I across be for little will those when mixes winded progression to region’s than be be only different, nature think the steps country and businesses us the Care X% impacted countries Asia-Pac than Vision about local in effectiveness every that more virus you range B&L group think very of that in believe Slide from will unlikely International taken Care of in XX, on revenue and uniform of roughly that are XXXX. revenues each that, in Bear come the the we America. of XX% the XXXX from Vision represents total The be our those long the to of all least the outcomes different the there think of depending regions for it's total in
assumptions Flip to with assumptions. to Slide COVID-XX start respect with XX, where we list broad major to our
the fall that far First, potential virus we and assuming that fall. use to the from of the health in resurgence with the deal better a will authorities prepared We event to recovery outbreak are initial the be learnings the assume of in resurgence.
not We place social in significant will local see put restrictions by authorities.
see economies assuming elective are resolves offices, of will to directives, shelter-in-place impact balance impact closing over to during respect global recover assumptions, businesses on that closing of as greatest Second, and QX providers our postponement XXXX. With the recovery surgeries. due situation the the the and retail we COVID-XX healthcare outlets, we business our
particularly units We dermatology some recovery B&L as levels COVID in begin of business most QX continue to part recover medical late and expect slowly, all businesses our Surgical, our XXXX, business ability QX we expect but of XXXX, more return our early in and certainly will to that dentistry to and several our the into business. pre perhaps of latter as have QX the the
change, range shape revised assumptions the outcomes sure. impacts want recovery the the On Russian revenue ruble, and the since the of $XX some on peso. various Slide XXXX for of guidance we therefore wider uncertainty EBITDA volatile of on back by regarding the developed presented depth XXXX that our the that Mexican the million. impacts multiple Canadian show our been based reduced for guidance account our on challenges point FX our dollar I by we for our review, out currencies of are COVID and normal. for XX, and COVID-XX euro, ranges the have businesses. February for bulk We million adjusted and of in each than provided rates curves the businesses $XXX to expectations scenarios our the of around Based guidance for the and Four us very
Our revised $X.XX and billion to $X.XX ranges $X.X to EBITDA $X.X for guidance billion. adjusted of billion are revenue billion of
with to We $XX be down roughly now due $XXX are FX. million on decrease about to basis, that expecting of million SG&A reported a
So of revenue in XXXX XXXX, reduce took light the on reduced a currency we for year by SG&A full constant $XXX our expectations basis. to roughly million steps
in with have and Finally, to reduced guidance our want with is are we the still in at remain billion. are revenue profit the $X of cushions. we expectations, excellent roughly flow We end generated cash positive. strongly shape. top Even of covenant low we that substantial reduced With mind, from guidance topic debt with state operating comfortable cash revised with our to that our activities a terms liquidity, agreements of compliance emphatically I ranges,
XXXX and $X.XXX no excuse We we billion payments we debt more ready quarter scheduled have – than to under access me revolving until XXXX. $X have a the have of billion which credit facility, first
for EBITDA XXXX adjusted EBITDA. X% currency, the and of range midpoint X% revenue to to Before was out we What awkward that X% turn we The note CAGR possibly at this the be we past and of we to our and EBITDA adjusted said guidance original on revising are we the way the the for was expect XXXX bridge, in in revenue and guidance to off please XXXX. a the have little of adjusted confusing. X% to expressed revenue guidance constant
would $X.XXX for today’s guidance, points Adjusted revenue was that starting and our $X.XX EBITDA. $X.XXX amounts million to for clarity, adjusted respectively. billion be billion those For and rates, FX $X.X for billion
be shows rates, XXXX the XX ranges by current confusing. I dollars FX which hope will at defined in the CAGRs Slide less
of cash near-term and detailed COVID-XX in our to footprints of through term of some and sales expansion and of The other that cash protect recovery. review of cost and comes for programs business each for our of remain investments, pairing the near-term duration our DUOBRII, flow or back, planned these COVID investments DTC longer our B&L protect our a by ensure units, dip of to profit both for we of the Solta, the impact eliminating example, the As for various depth do that Europe business steps positive took and earnings part our deferral of and our units. solidly best for and we to for outlook at was flow deferring
units prior ranges. us revise longer our forecast the was our for we impacts update COVID-XX of the our revenue in of see range and longer revising starting to the adjusted for at We and Absent CAGR for same X% of FX Please changes all guidance. our COVID-XX X% in business toX% caused and only review points term revised XXXX. maintained current outlook Today, X% impacts Slide and to we using it combination rates. a both not for are EBITDA. continually factor XX the guidance outlook CAGR that our for to COVID-XX, our of was ranges have CAGR XXXX-dollar would the
Slide by currency we COVID-XX. impact bridge. XXXX of the $XXX for due million revenue to our range, almost guidance constant entirely the to XX are of expectation reducing Turn the our a midpoint At on basis,
a to expect reductions profit and of spend. some offset of SG&A through decrease gross see our also we lost modest R&D expected that that You in
let that, back turn With me you, it to Joe.
